Skip to main content
SpringerLink
Log in

Cardiovascular Risk in Obese Hypertensive Patients Taking Various Antihypertensive Drugs

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: Obese patients often present with multiple co-morbid conditions, including hypertension, which are associated with an increased cardiovascular (CV) risk. We aimed to assess the risk factor profiles of primary-care patients with obesity and hypertension in order to estimate their fatal CV risk in total and according to use of various antihypertensive drugs.

Methods: This was a post-hoc analysis of data from a recent observational study involving 72 479 hypertensive patients in 6989 general practices across Germany. Almost all patients (92.3%) were overweight or obese. The 10-year risk for fatal CV events was determined using the SCORE algorithm as published by the European Society of Cardiology.

Results: Overall, 68% of patients had one or more diseases or conditions in addition to obesity and hypertension. The 10-year fatal CV risk was lowest in the youngest normal weight group (1.7%), and highest in the oldest obese group (26%). Men had a higher risk than women, and risk rose with increasing age. The risk factor profile appeared to differ between patients treated with various antihypertensive classes, e.g. angiotensin II type 1 receptor antagonists were associated with lower risk, diuretics with higher risk. There were moderate differences within drug classes.

Conclusions: According to this cross-sectional data, fatal CV risk is strongly increased in obese patients, especially in men and in older age groups. While there were strong associations between use of certain drugs and metabolic risk markers and overall fatal CV risk, the causality of these associations remains to be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17(10): 904–10

    Article  PubMed  Google Scholar 

  2. Bramlage P, Wittchen HU, Pittrow D, et al. Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord 2004; 28(10): 1299–308

    Article  PubMed  CAS  Google Scholar 

  3. Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data. Am J Clin Nutr 1997; 66(4 Suppl.): 1044S–50S

    PubMed  CAS  Google Scholar 

  4. Jousilahti P, Tuomilehto J, Vartiainen E, et al. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996; 93(7): 1372–9

    Article  PubMed  CAS  Google Scholar 

  5. Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162(16): 1867–72

    Article  PubMed  Google Scholar 

  6. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10Suppl. 2: 97–104S

    Article  Google Scholar 

  7. Frijling BD, Lobo CM, Keus IM, et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educ Couns 2004; 52(1): 47–53

    Article  PubMed  Google Scholar 

  8. MacMahon S, Cutler J, Brittain E, et al. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987; 8Suppl. B: 57–70

    Article  PubMed  Google Scholar 

  9. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60(2): 135–42

    Article  PubMed  CAS  Google Scholar 

  10. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987–1003

    Article  PubMed  CAS  Google Scholar 

  11. Sharma A, Bramlage P, Kirch W. Antihypertensive efficacy of irbesartan and predictors of response in obesity-associated hypertension. Clin Drug Inv 2005; 25(12): 1–11

    Google Scholar 

  12. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290(2): 199–206

    Article  PubMed  Google Scholar 

  13. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76–9

    Article  PubMed  Google Scholar 

  14. Sharma A, Wittchen H, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross sectional study. J Hypertens 2004; 22: 479–86

    Article  PubMed  CAS  Google Scholar 

  15. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the AHA task force on risk reduction. Circulation 1998; 97(18): 1876–87

    Article  PubMed  CAS  Google Scholar 

  16. 16. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320(7236): 705–8

    Article  Google Scholar 

  17. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care. Curr Med Res Opin 2004; 20(10): 1625–31

    Article  PubMed  CAS  Google Scholar 

  18. Wittchen HU, Glaesmer H, Marz W, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates. The DETECT program. Curr Med Res Opin 2005; 21(4): 619–30

    Article  PubMed  Google Scholar 

  19. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004; 79(3): 379–84

    PubMed  CAS  Google Scholar 

  20. Wannamethee SG, Shaper AG, Morris RW, et al. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr 2005; 81(6): 1313–21

    PubMed  CAS  Google Scholar 

  21. De Simone G, Wachteil K, Palmieri V, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 2005; 111(15): 1924–31

    Article  Google Scholar 

  22. Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and betablockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Arch Intern Med 1999; 159(6): 551–8

    Article  PubMed  CAS  Google Scholar 

  23. Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

    Article  Google Scholar 

  24. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–71

    Article  PubMed  CAS  Google Scholar 

  25. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326(7404): 1427

    Article  PubMed  CAS  Google Scholar 

  26. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44(1): 12–9

    Article  PubMed  CAS  Google Scholar 

  27. Bramlage P, Bramlage C, Kirch W. Antihypertensive drug utilisation in obese patients [in German]. Med Klin (Munich) 2005; 100: 804–9

    Article  Google Scholar 

  28. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by a research grant from Sanofi-Aventis Deutschland GmbH, Berlin, Germany. The authors wish to acknowledge the statistical advice provided by Stefan Bruns, Winicker Norimed, Nürnberg, Germany. Peter Bramlage has received consulting fees and research support from Sanofi-Aventis. The other authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Technical University, Dresden, Germany

    Christoph Schindler, Peter Bramlage, Martin Thoenes & Wilhelm Kirch

  2. Department of Medicine, Nephrology and Rheumatology, Georg-August-University Göttingen, Göttingen, Germany

    Carsten Bramlage

Authors
  1. Christoph Schindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Bramlage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Thoenes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carsten Bramlage
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wilhelm Kirch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Schindler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schindler, C., Bramlage, P., Thoenes, M. et al. Cardiovascular Risk in Obese Hypertensive Patients Taking Various Antihypertensive Drugs. Clin. Drug Investig. 27, 707–717 (2007). https://doi.org/10.2165/00044011-200727100-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200727100-00006

Keywords

Search

Navigation